TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington Disease

Interventions

DRUG: Ethyl-EPA (Miraxion™)

Sponsor

Amarin Neuroscience Ltd

Collaborators

[object Object]